1 / 11

RA190

RA190. Small Molecule Proteasome Inhibitor for Cancer Therapy. Targeting the proteasome…. Proteasomal degradation of tumor suppressor proteins is found in many cancers apoptosis arrest sustained cell proliferation. Current proteasome inhibitors: grave side effects disease resistance .

binta
Télécharger la présentation

RA190

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RA190 Small Molecule Proteasome Inhibitor for Cancer Therapy

  2. Targeting the proteasome… • Proteasomal degradation of tumor suppressor proteins is found in many cancers • apoptosis arrest • sustained cell proliferation

  3. Current proteasome inhibitors: • grave side effects • disease resistance • RA190: • Reduced toxicity • novel mechanism of action overcomes drug resistance • Preferential targeting of transformed cells

  4. Mechanism Of Action • Binds to ubiquitin receptor RPN13 • RPN13 is part of the 19S Regulatory Cap • Responsible for removing Ub from target proteins • Proteasome inhibited • Misfolded protein buildup

  5. The Drug • Orally available • Promising toxicity profile • Works on tumors resistant to bortezumib • Active against cervical and ovarian cancer, and Multiple Myeloma

  6. The Business What we do: Find cancer cure Who we are: CanCure Inc. “Because we CanCure cancer*!” * By cancer, we mean cervical and ovarian cancer, and multiple myeloma.

  7. The Team • Looking to build a highly dedicated, talented, and experienced management team: • Looking for: • CEO: preferably with product launch experience • CFO • CMO • CRO • VPs • Etc…

  8. The Market • Ovarian cancer: 17th most common cancer • 21,980 estimated new cases in 2014 • 14,270 deaths • Cervical cancer: 21st most common cancer • 12,360 estimated new cases in 2014 • 4,020 deaths • Multiple myeloma: 14th most common cancer • 24,050 estimated new cases in 2014 • 11,090 deaths *From NCI SEER statistics 2014

  9. Financial Projections

  10. Growth Strategy • Develop companion diagnostic test for RA190 • Explore RA190 in other cancers Exit Strategy • Sell company to large pharma

More Related